DYN

Dyne downgraded at J.P. Morgan on Novartis setback (DYN:NASDAQ)

Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class (NASDAQ:DYN)

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed

Dyne Therapeutics stock faces pressure after rival drug fails trial

Why is Dyne Therapeutics stock plummeting today?

Novartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE)

Dyne therapeutics director Jason Rhodes sells $65.2m of common stock

Dyne therapeutics CFO Erick Lucera sells $47,225 in stock

Dyne Therapeutics stock hits 52-week high at 25.06 USD

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Dyne Therapeutics (DYN) Prices Upsized Share Offering, Is The Valuation Still Compelling?

Dyne Therapeutics Launches 18.3M-Share Offering at $20.50; Nets ~$352M, Greenshoe to $405M

Dyne Therapeutics shares slide after pricing $375 million public offering (NASDAQ:DYN)